Flaharty Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Flaharty Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-32,000	Closed	-$157K	–	127
2024 Q1	$157K	Buy	+32,000	New	+$189K	0.02%	115
2023 Q2	–	Sell	-6,952	Closed	-$224K	–	117
2023 Q1	$224K	Sell	6,952 -6,500	-48%	-$203K	0.04%	104
2022 Q4	$248K	Buy	13,452 +1,000	+8%	+$22.9K	0.05%	97
2022 Q3	$336K	Sell	12,452 -5,000	-29%	-$101K	0.07%	81
2022 Q2	$241K	Buy	17,452 +2,000	+13%	+$30.8K	0.05%	99
2022 Q1	$301K	Hold	15,452	–	–	0.06%	89
2021 Q4	$252K	Buy	+15,452	New	+$258K	0.05%	110

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Flaharty Asset Management's RVNC Position: Q2 2024 in Review

Flaharty Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2024, closing a stake of 32,000 shares — an estimated $157K sold.

Flaharty Asset Management first reported a position in RVNC in Q4 2021 and held it in 7 quarters. The position peaked at $336K in Q3 2022. 173 funds tracked by Wall St. Rank hold RVNC as of Q2 2024.

Flaharty Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q2 2024 after selling out during the quarter.
Flaharty Asset Management sold 32,000 Revance Therapeutics, Inc. shares in Q2 2024, an estimated $157K.
Flaharty Asset Management first reported a position in Revance Therapeutics, Inc. in Q4 2021 and held it in 7 quarters.
Flaharty Asset Management's Revance Therapeutics, Inc. position peaked at $336K in Q3 2022.
173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2024.

Based on Flaharty Asset Management's 13F filing for Q2 2024, filed 1 Aug 2024.